The Brown University Child and Adolescent Psychopharmacology Update articles from June 2007

The Brown University Child and Adolescent Psychopharmacology Update archives from June 2007

Low suicide risk from second-generation antidepressants in children and adolescents.(SSRI Safety Update)
June 1, 2007... precis * A new study finds a small (less than 1%) but significant risk of suicidal ideation/suicide attempt in pediatric patients receiving second-generation antidepressants compared with placebo; antidepressants were most effective...

Drug review for childhood anxiety shows good evidence for SSRIs.(Pediatric Anxiety Disorders)(selective serotonin reuptake inhibitors)
June 1, 2007... precis * Review of studies published between 1985 and 2006 on the pharmacological treatment of pediatric anxiety disorders, with an emphasis on randomized controlled trials * Selective serotonin reuptake inhibitor (SSRI) generally...

An overview of ziprasidone in children and adolescents.
June 1, 2007... In a previous issue of The Update (June 2005), our lead article presented an overview of a prospective, open-label study of ziprasidone for Tourette's syndrome published in the Journal of the American Academy of Child and Adolescent...

Omega-3 fatty acids examined in autism, associated symptoms.(What's New In Research)
June 1, 2007... precis * 6-week double-blind, placebo-controlled pilot study of 12 autistic boys randomized to daily treatment with omega-3 * The study found large effect sizes in improvements in hyperactivity and stereotypy with omega-3 treatment...

AAP guidelines for PC physicians treating children with ADD.(News Note)(American Academy of Pediatrics, primary care physicians, attention deficit hyperactivity disorder )(Brief article)
June 1, 2007... The American Academy of Pediatrics has released recommendations for primary care physicians treating children with attention-deficit/hyperactivity disorder (ADHD). The recommendations call for a thorough evaluation and diagnosis of ADHD prior...

Oxcarbazepine (Trileptal) treatment for autism and disruptive behaviors.(Case Reports)
June 1, 2007... This is the first report of oxcarbazepine for treating disruptive behaviors in autism. The author presents 3 cases of autistic youths, also receiving behavioral therapy, who benefited from oxcarbazepine for disruptive behavior. Although...

First-time generic approval of zolpidem.(From the FDA)(Brief article)
June 1, 2007... Final approval has been granted (April 23, 2007) for the first generic version of Ambien (zolpidem) immediate-release tablets, indicated for the short-term treatment of insomnia. The tablets are available in 5-mg and 10-mg formulations. A...

New FDA warnings on anti-depressant use and suicidal thoughts and behavior.(From the FDA)
June 1, 2007... The U.S. Food and Drug Administration (FDA) has requested all manufacturers of antidepressants to update existing black box labeling to include warnings about the increased risks of suicidal thinking and behavior in young adults ages 18 to 24...

Ziprasidone (generic) Ziprasidone Hydrochloride (HCl) (capsules) Ziprasidone Mesylate (intramuscular injection): Geodon (Brand).(YOUR MEDICATION INFORMATION)(Drug overview)
June 1, 2007... CLASSIFICATION: Atypical antipsychotic. COMMON USAGE: Ziprasidone is indicated for the treatment of schizophrenia, with injectable ziprasidone (intramuscular) indicated for the rapid treatment of acute agitation in schizophrenic patients....